Review on Characteristics and Analytical Methods of Rivaroxaban

Reçber, Tuba; Haznedaroğlu, İbrahim C.; Çelebi̇er, Mustafa

doi:10.1080/10408347.2020.1839735

Cited by 14 publications

(8 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 , the functional coating consists of the following modules: (i) self-regulating antithrombotic system realized by thrombin-sensitive nanogels loaded with an anticoagulant. Triggered by environmental thrombin, the nanogels, based on oxidized hyaluronic acid (Ox-HA) with thrombin-cleavable peptide cross-linkers, rapidly released the factor Xa (FXa) inhibitor rivaroxaban (RIVA) ( 32 ), blocking the coagulation cascade. The level of coagulation activity directly affected the anticoagulant release of the coating, comparable to the feedback-controlled effect of the endothelium.…”

Section: Introductionmentioning

confidence: 99%

A thrombin-triggered self-regulating anticoagulant strategy combined with anti-inflammatory capacity for blood-contacting implants

Wang

Zhou

et al. 2022

Sci. Adv.

View full text Add to dashboard Cite

Interrelated coagulation and inflammation are impediments to endothelialization, a prerequisite for the long-term function of cardiovascular materials. Here, we proposed a self-regulating anticoagulant coating strategy combined with anti-inflammatory capacity, which consisted of thrombin-responsive nanogels with anticoagulant and anti-inflammatory components. As an anticoagulant, rivaroxaban was encapsulated in nanogels cross-linked by thrombin-cleavable peptide and released upon the trigger of environmental thrombin, blocking the further coagulation cascade. The superoxide dismutase mimetic Tempol imparted the antioxidant property. Polyphenol epigallocatechin gallate (EGCG), in addition to its anti-inflammatory function in synergy with Tempol, also acted as a weak cross-linker to stabilize the coating. The effectiveness and versatility of this coating were validated using two typical cardiovascular devices as models, biological valves and vascular stents. It was demonstrated that the coating worked as a precise strategy to resist coagulation and inflammation, escorted reendothelialization on the cardiovascular devices, and provided a new perspective for designing endothelium-like functional coatings.

show abstract

Section: Introductionmentioning

confidence: 99%

A thrombin-triggered self-regulating anticoagulant strategy combined with anti-inflammatory capacity for blood-contacting implants

Wang

Zhou

et al. 2022

Sci. Adv.

View full text Add to dashboard Cite

show abstract

“…A number of other targeted proteomic studies have reported additional biomarkers associated with risk of bleeding in patients with acute coronary syndromes (Hagström et al, 2016;Hijazi et al, 2016). In a study comparing treatment with warfarin and rivaroxaban, nine metaproteins were shown to be differentially expressed (Mueck et al, 2014;Harter et al, 2015;Kaye et al, 2017;Reçber et al, 2020).…”

Section: Proteomicsmentioning

confidence: 99%

Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches

et al. 2022

View full text Add to dashboard Cite

Heparin-induced thrombocytopenia (HIT) is an unpredictable, complex, immune-mediated adverse drug reaction associated with a high mortality. Despite decades of research into HIT, fundamental knowledge gaps persist regarding HIT likely due to the complex and unusual nature of the HIT immune response. Such knowledge gaps include the identity of a HIT immunogen, the intrinsic roles of various cell types and their interactions, and the molecular basis that distinguishes pathogenic and non-pathogenic PF4/heparin antibodies. While a key feature of HIT, thrombocytopenia, implicates platelets as a seminal cell fragment in HIT pathogenesis, strong evidence exists for critical roles of multiple cell types. The rise in omic technologies over the last decade has resulted in a number of agnostic, whole system approaches for biological research that may be especially informative for complex phenotypes. Applying multi-omics techniques to HIT has the potential to bring new insights into HIT pathophysiology and identify biomarkers with clinical utility. In this review, we review the clinical, immunological, and molecular features of HIT with emphasis on key cell types and their roles. We then address the applicability of several omic techniques underutilized in HIT, which have the potential to fill knowledge gaps related to HIT biology.

show abstract

“…The difference in the comparison results of the three drugs may be related to the antithrombotic mechanism of each drug. Rivaroxaban is a direct Xa I, which selectively blocks the active site of Xa and does not require cofactors, such as antithrombin III (AT III) [16] . Dalteparin sodium is a kind of LMWH with a small molecular weight.…”

Section: /24mentioning

confidence: 99%

Effectiveness of tranexamic acid combined with different antithrombotic agents in total knee arthroplasty：a prospective randomized study

Zhou

Wang

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: To observe the effect of tranexamic acid (TXA) in combination with different antithrombotic agents in patients after initial unilateral total knee arthroplasty (TKA). Methods: One hundred and eighty patients with initial unilateral TKA from October 2020 to December 2021 were selected, all of whom were given intraoperative intravenous 60 mg/kg TXA and were divided into the rivaroxaban group, the dalteparin sodium group, and the aspirin group according to the application of antithrombotic drugs, with 60 cases each. The rivaroxaban group received 10 mg of oral Rivaroxaban 12 h after surgery, the dalteparin sodium group received 2500 U of subcutaneous dalteparin sodium, and the aspirin group received 100 mg of oral aspirin once daily for four weeks. The incidence of various hematological indices, transfusion rate, blood loss, and complications (bleeding complications and thrombotic complications) were observed in the three groups before and after treatment. Results: The hemoglobin levels were significantly lower in the Rivaroxaban, dalteparin sodium, and aspirin groups on days 1, 3, and 5 after treatment compared with those before treatment (P<0.05). The hemoglobin level was higher in the aspirin group than in the rivaroxaban and dalteparin sodium groups on days 1, 3, and 5 after treatment (P<0.05) and in the rivaroxaban group than in the dalteparin sodium group (P<0.05). When comparing the transfusion rates of the three groups, the transfusion rate in the dalteparin sodium group (20.0%) was significantly higher than that in the rivaroxaban group (6.7%) and the aspirin group (5.0%), with P<0.05. When comparing the post-treatment drainage and total blood loss in the three groups, the post-treatment drainage and total blood loss in the aspirin group were significantly lower than those in the rivaroxaban and dalteparin sodium groups (P<0.05), and the post-treatment drainage and total blood loss in the rivaroxaban group were significantly lower than those in the rivaroxaban and dalteparin sodium groups (P<0.05). Total blood loss was significantly lower in the rivaroxaban group than in the dalteparin sodium group (P<0.05). The incidence of bleeding complications in the three groups was significantly higher in the rivaroxaban group (26.7%) than in the dalteparin sodium group (10.0%) and the aspirin group (8.3%), with P<0.05. There was no significant difference in the incidence of thrombotic complications between the three groups of patients (P>0.05). Conclusion: Aspirin, Rivaroxaban, and dalteparin sodium effectively prevent venous thromboembolism after total knee arthroplasty. The additional benefit of aspirin in reducing total blood loss, transfusion rates, and bleeding complication rates supports the use of aspirin as a suitable alternative to other anticoagulants to prevent thrombosis after total knee arthroplasty in low-risk patients. Trial registration: The trial was registered in the Chinese Clinical Trial Registry (ChiCTR2200060169). Registered date: 21/05/2022

show abstract

Review on Characteristics and Analytical Methods of Rivaroxaban

Cited by 14 publications

References 72 publications

A thrombin-triggered self-regulating anticoagulant strategy combined with anti-inflammatory capacity for blood-contacting implants

A thrombin-triggered self-regulating anticoagulant strategy combined with anti-inflammatory capacity for blood-contacting implants

Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches

Effectiveness of tranexamic acid combined with different antithrombotic agents in total knee arthroplasty：a prospective randomized study

Contact Info

Product

Resources

About